Emerging biological therapies for the treatment of age-related macular degeneration.

Asahi, Masumi G; Avaylon, Jaycob; Wallsh, Josh; Gallemore, Ron P

Asahi, Masumi G; Avaylon, Jaycob; Wallsh, Josh; Gallemore, Ron P.

Affiliation

Asahi MG; Department of Ophthalmology, George Washington University, Washington, DC, USA.
Avaylon J; California Northstate University, College of Medicine, Elk Grove, CA, USA.
Wallsh J; Department of Ophthalmology, Albany Medical College, Albany, NY, USA.
Gallemore RP; Retina Macula Institute, Torrance, CA, USA.

Expert Opin Emerg Drugs ; 26(2): 193-207, 2021 06.

Article in En | MEDLINE | ID: mdl-34030572

Subject(s)

Biological Therapy/methods; Choroidal Neovascularization/therapy; Macular Degeneration/therapy; Angiogenesis Inhibitors/administration & dosage; Angiogenesis Inhibitors/pharmacology; Animals; Choroidal Neovascularization/pathology; Disease Progression; Genetic Therapy/methods; Humans; Intravitreal Injections; Macular Degeneration/pathology; Middle Aged; Risk Factors; Stem Cell Transplantation/methods; Vascular Endothelial Growth Factor A/antagonists & inhibitors

Key words

Age-related macular degeneration; biologic; emerging; exudative; gene therapy; nonexudative; stem cell therapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biological Therapy / Choroidal Neovascularization / Macular Degeneration Type of study: Etiology_studies / Risk_factors_studies Limits: Animals / Humans / Middle aged Language: En Journal: Expert Opin Emerg Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google